{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:25:45Z","timestamp":1794486345482,"version":"4.9.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Structural Biology"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.crstbi.2024.100128","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T09:46:20Z","timestamp":1705830380000},"page":"100128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Inhibition of Plasmodium falciparum plasmepsins by drugs targeting HIV-1 protease: A way forward for antimalarial drug discovery"],"prefix":"10.1016","volume":"7","author":[{"given":"Vandana","family":"Mishra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Deshmukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishan","family":"Rathore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satadru","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Patankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alla","family":"Gustchina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Wlodawer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rickey Y.","family":"Yada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasenjit","family":"Bhaumik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.crstbi.2024.100128_bib1","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa1200501","article-title":"Antiretroviral agents and Prevention of malaria in HIV-infected Ugandan Children","volume":"367","author":"Achan","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.crstbi.2024.100128_bib2","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1128\/AAC.50.2.639-648.2006","article-title":"Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria","volume":"50","author":"Andrews","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.crstbi.2024.100128_bib3","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1107\/S0907444902014695","article-title":"Structures of Ser205 mutant plasmepsin II from Plasmodium falciparum at 1.8 \u00c5 in complex with the inhibitors rs367 and rs370","volume":"58","author":"Asojo","year":"2002","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"10.1016\/j.crstbi.2024.100128_bib4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0022-2836(03)00036-6","article-title":"Novel uncomplexed and complexed structures of plasmepsin II, an aspartic protease from Plasmodium falciparum","volume":"327","author":"Asojo","year":"2003","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.crstbi.2024.100128_bib5","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1073\/pnas.022630099","article-title":"Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine","volume":"99","author":"Banerjee","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.crstbi.2024.100128_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep31420","article-title":"Understanding the structural basis of substrate recognition by Plasmodium falciparum plasmepsin v to aid in the design of potent inhibitors","volume":"6","author":"Bedi","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.crstbi.2024.100128_bib7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/cmdc.201100490","article-title":"Experimental and computational active site Mapping as a starting Point to Fragment\u2010based lead discovery","volume":"7","author":"Behnen","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.crstbi.2024.100128_bib8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.bbapap.2011.04.008","article-title":"Structural studies of vacuolar plasmepsins","volume":"1824","author":"Bhaumik","year":"2012","journal-title":"Biochim. Biophys. Acta, Proteins Proteomics"},{"key":"10.1016\/j.crstbi.2024.100128_bib9","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nature08728","article-title":"An aspartyl protease directs malaria effector proteins to the host cell","volume":"463","author":"Boddey","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.crstbi.2024.100128_bib10","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/cmdc.200600223","article-title":"Achiral, cheap, and potent inhibitors of plasmepsins I, II, and IV","volume":"1","author":"Boss","year":"2006","journal-title":"ChemMedChem"},{"key":"10.1016\/j.crstbi.2024.100128_bib11","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.crstbi.2024.100128_bib12","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S1471-4922(01)02037-2","article-title":"Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets","volume":"17","author":"Coombs","year":"2001","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.crstbi.2024.100128_bib13","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0035-9203(97)90110-3","article-title":"An alternative to serum for cultivation of Plasmodium falciparum in vitro","volume":"91","author":"Cranmer","year":"1997","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.crstbi.2024.100128_bib14","doi-asserted-by":"crossref","first-page":"W615","DOI":"10.1093\/nar\/gkh398","article-title":"MOLPROBITY: structure validation and all-atom contact analysis for nucleic acids and their complexes","volume":"32","author":"Davis","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.crstbi.2024.100128_bib15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMoa0808859","article-title":"Artemisinin resistance in Plasmodium falciparum malaria","volume":"361","author":"Dondorp","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.crstbi.2024.100128_bib16","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: model-building tools for molecular graphics","volume":"60","author":"Emsley","year":"2004","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"10.1016\/j.crstbi.2024.100128_bib17","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.chom.2020.02.005","article-title":"Dual plasmepsin-targeting antimalarial agents Disrupt multiple stages of the malaria parasite life cycle","volume":"27","author":"Favuzza","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.crstbi.2024.100128_bib18","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/17425255.2019.1604685","article-title":"Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment","volume":"15","author":"Gong","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.crstbi.2024.100128_bib19","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ijantimicag.2009.09.016","article-title":"In vitro interactions between antiretroviral protease inhibitors and artemisinin endoperoxides against Plasmodium falciparum","volume":"35","author":"He","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.crstbi.2024.100128_bib20","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1086\/594369","article-title":"HIV protease inhibitors inhibit the development of Preerythrocytic-stage Plasmodium parasites","volume":"199","author":"Hobbs","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.crstbi.2024.100128_bib21","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.str.2022.03.018","article-title":"Basis for drug selectivity of plasmepsin IX and X inhibition in Plasmodium falciparum and vivax","volume":"30","author":"Hodder","year":"2022","journal-title":"Structure"},{"key":"10.1016\/j.crstbi.2024.100128_bib22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","article-title":"VMD: Visual molecular dynamics","volume":"14","author":"Humphrey","year":"1996","journal-title":"J. Mol. Graph."},{"key":"10.1016\/j.crstbi.2024.100128_bib23","doi-asserted-by":"crossref","first-page":"6890","DOI":"10.1074\/jbc.M412086200","article-title":"Distal substrate interactions enhance plasmepsin activity","volume":"280","author":"Istvan","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.crstbi.2024.100128_bib24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1021\/ml4004952","article-title":"Plasmepsin inhibitory activity and structure-guided optimization of a potent hydroxyethylamine-based antimalarial hit","volume":"5","author":"Jaudzems","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.crstbi.2024.100128_bib25","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1107\/S0907444909047337","volume":"66","author":"Kabsch","year":"2010","journal-title":"XDS. Acta Crystallogr. D. Biol. Crystallogr."},{"key":"10.1016\/j.crstbi.2024.100128_bib26","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/pro.4279","article-title":"Structures of plasmepsin X from Plasmodium falciparum reveal a novel inactivation mechanism of the zymogen and molecular basis for binding of inhibitors in mature enzyme","volume":"31","author":"Kesari","year":"2022","journal-title":"Protein Sci."},{"key":"10.1016\/j.crstbi.2024.100128_bib27","doi-asserted-by":"crossref","first-page":"6203","DOI":"10.1128\/AAC.00899-15","article-title":"The glucose transporter PfHT1 is an antimalarial target of the HIV protease inhibitor lopinavir","volume":"59","author":"Kraft","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.crstbi.2024.100128_bib28","doi-asserted-by":"crossref","first-page":"418","DOI":"10.2307\/3280287","article-title":"Synchronization of Plasmodium falciparum erythrocytic stages in culture","volume":"65","author":"Lambros","year":"1979","journal-title":"J. Parasitol."},{"key":"10.1016\/j.crstbi.2024.100128_bib29","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1002\/prot.22711","article-title":"Improved side\u2010chain torsion potentials for the Amber ff99SB protein force field","volume":"78","author":"Lindorff\u2010Larsen","year":"2010","journal-title":"Proteins Struct. Funct. Bioinforma."},{"key":"10.1016\/j.crstbi.2024.100128_bib30","doi-asserted-by":"crossref","first-page":"14121","DOI":"10.1021\/acs.jmedchem.2c01336","article-title":"Discovery and Characterization of potent, Efficacious, Orally available antimalarial plasmepsin X inhibitors and Preclinical Safety Assessment of UCB7362","volume":"65","author":"Lowe","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.crstbi.2024.100128_bib31","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1128\/AAC.01043-07","article-title":"New active drugs against liver stages of Plasmodium Predicted by molecular topology","volume":"52","author":"Mahmoudi","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.crstbi.2024.100128_bib32","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/0022-2836(68)90205-2","article-title":"Solvent content of protein crystals","volume":"33","author":"Matthews","year":"1968","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.crstbi.2024.100128_bib33","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4269\/ajtmh.2010.09-0427","article-title":"Short report: HIV protease inhibitors, indinavir or nelfinavir, augment antimalarial action of artemisinin in vitro","volume":"82","author":"Mishra","year":"2010","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.crstbi.2024.100128_bib34","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1111\/febs.14598","article-title":"Deciphering the mechanism of potent peptidomimetic inhibitors targeting plasmepsins \u2013 biochemical and structural insights","volume":"285","author":"Mishra","year":"2018","journal-title":"FEBS J."},{"key":"10.1016\/j.crstbi.2024.100128_bib35","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.crstbi.2024.100128_bib36","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1107\/S0907444996012255","article-title":"Refinement of Macromolecular structures by the Maximum-Likelihood method","volume":"53","author":"Murshudov","year":"1997","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"10.1016\/j.crstbi.2024.100128_bib37","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1126\/science.aan1478","article-title":"Plasmepsins IX and X are essential and druggable mediators of malaria parasite egress and invasion","volume":"358","author":"Nasamu","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.crstbi.2024.100128_bib38","doi-asserted-by":"crossref","first-page":"54088","DOI":"10.1074\/jbc.M409605200","article-title":"Genetic Disruption of the Plasmodium falciparum digestive vacuole plasmepsins demonstrates their functional redundancy","volume":"279","author":"Omara-Opyene","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.crstbi.2024.100128_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0201556","article-title":"Deciphering the targets of retroviral protease inhibitors in Plasmodium berghei","volume":"13","author":"Onchieku","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.crstbi.2024.100128_bib40","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1107\/S0907444906005270","article-title":"Optimal description of a protein structure in terms of multiple groups undergoing TLS motion","volume":"62","author":"Painter","year":"2006","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"10.1016\/j.crstbi.2024.100128_bib41","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1128\/AAC.49.7.2983-2985.2005","article-title":"Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors","volume":"49","author":"Parikh","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.crstbi.2024.100128_bib42","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1126\/science.aaf8675","article-title":"A multistage antimalarial targets the plasmepsins IX and X essential for invasion and egress","volume":"358","author":"Pino","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.crstbi.2024.100128_bib43","doi-asserted-by":"crossref","first-page":"23837","DOI":"10.1074\/jbc.M501519200","article-title":"X-ray structure of plasmepsin II complexed with a potent achiral inhibitor","volume":"280","author":"Prade","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.crstbi.2024.100128_bib44","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.crstbi.2024.100128_bib45","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1107\/S2053230X15022049","article-title":"Structures of plasmepsin II from Plasmodium falciparum in complex with two hydroxyethylamine-based inhibitors","volume":"71","author":"Recacha","year":"2015","journal-title":"Acta Crystallogr. Sect. Struct. Biol. Commun."},{"key":"10.1016\/j.crstbi.2024.100128_bib46","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1242\/jeb.00589","article-title":"Antimalarial drug discovery: old and new approaches","volume":"206","author":"Rosenthal","year":"2003","journal-title":"J. Exp. Biol."},{"key":"10.1016\/j.crstbi.2024.100128_bib47","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/wcms.1121","article-title":"An overview of the Amber biomolecular simulation package","volume":"3","author":"Salomon\u2010Ferrer","year":"2013","journal-title":"WIREs Comput. Mol. Sci."},{"key":"10.1016\/j.crstbi.2024.100128_bib48","first-page":"363","article-title":"Structural analysis of plasmepsin II - a comparison with human aspartic proteases","author":"Silva","year":"1996","journal-title":"7th Int. Conf. Aspartic Proteinases"},{"key":"10.1016\/j.crstbi.2024.100128_bib49","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1086\/425584","article-title":"Antiretrovirals as antimalarial agents","volume":"190","author":"Skinner\u2010Adams","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.crstbi.2024.100128_bib50","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/jcc.20291","article-title":"GROMACS: Fast, flexible, and free","volume":"26","author":"Van Der Spoel","year":"2005","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.crstbi.2024.100128_bib51","doi-asserted-by":"crossref","first-page":"W296","DOI":"10.1093\/nar\/gky427","article-title":"SWISS-MODEL: homology modelling of protein structures and complexes","volume":"46","author":"Waterhouse","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.crstbi.2024.100128_bib52","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(13)60024-0","article-title":"Malaria","volume":"383","author":"White","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.crstbi.2024.100128_bib53","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1107\/S0907444910045749","article-title":"Overview of the CCP 4 suite and current developments","volume":"67","author":"Winn","year":"2011","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"10.1016\/j.crstbi.2024.100128_bib54","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1186\/s12936-015-0940-8","article-title":"Quantification of Plasmodium ex vivo drug susceptibility by flow cytometry","volume":"14","author":"Wirjanata","year":"2015","journal-title":"Malar. J."},{"key":"10.1016\/j.crstbi.2024.100128_bib55","series-title":"World Malaria Report 2022","author":"World Health Organization","year":"2022"},{"key":"10.1016\/j.crstbi.2024.100128_bib56","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.2307\/3281094","article-title":"Plasmodium falciparum: modifications of the in vitro culture conditions improving parasitic yields","volume":"68","author":"Zolg","year":"1982","journal-title":"J. Parasitol."}],"container-title":["Current Research in Structural Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2665928X24000059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2665928X24000059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T23:12:57Z","timestamp":1718579577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2665928X24000059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":56,"alternative-id":["S2665928X24000059"],"URL":"https:\/\/doi.org\/10.1016\/j.crstbi.2024.100128","relation":{},"ISSN":["2665-928X"],"issn-type":[{"value":"2665-928X","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of Plasmodium falciparum plasmepsins by drugs targeting HIV-1 protease: A way forward for antimalarial drug discovery","name":"articletitle","label":"Article Title"},{"value":"Current Research in Structural Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.crstbi.2024.100128","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100128"}}